Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathon B Cohen

Showing results (41-50 of 129) with videos related to

Pageof 13
Sort By:
Leukemia & Lymphoma|June 19, 2018
Deferred treatment is a safe and viable option for selected patients with mantle cell lymphomaOscar Calzada, Jeffrey M Switchenko, Joseph J Maly, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 10, 2015
Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphomaJonathon B Cohen, Amy S Ruppert, Nyla A Heerema, et al.
Blood|September 28, 2019
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemiaMatthew Lunning, Julie Vose, Loretta Nastoupil, et al.
Cancer|June 22, 2021
Surveillance imaging during first remission in follicular lymphoma does not impact overall survivalMax L Goldman, Jimmy J Mao, Christopher S Strouse, et al.
British Journal of Haematology|August 8, 2015
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphomaJonathon B Cohen, Jeffrey M Switchenko, Jean L Koff, et al.
The Journal of Clinical Investigation|July 21, 2022
Herpes simplex virus lymphadenitis is associated with tumor reduction in a patient with chronic lymphocytic leukemiaAndres Chang, Anton M Sholukh, Andreas Wieland, et al.
Cancer|April 9, 2026
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025Alexey V Danilov, Catherine C Coombs, Tycel Phillips, et al.
Hematological Oncology|January 10, 2017
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" studyNarendranath Epperla, Mehdi Hamadani, Amanda F Cashen, et al.
Ejhaem|October 17, 2024
Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapyNicole Lamanna, Constantine S Tam, Jennifer A Woyach, et al.
The Lancet. Haematology|February 3, 2019
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trialLoretta J Nastoupil, Matthew A Lunning, Julie M Vose, et al.
Pageof 13

Showing results (41-50 of 129) with videos related to

Sort By:
Pageof 13
Leukemia & Lymphoma|June 19, 2018
Deferred treatment is a safe and viable option for selected patients with mantle cell lymphomaOscar Calzada, Jeffrey M Switchenko, Joseph J Maly, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 10, 2015
Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphomaJonathon B Cohen, Amy S Ruppert, Nyla A Heerema, et al.
Blood|September 28, 2019
Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemiaMatthew Lunning, Julie Vose, Loretta Nastoupil, et al.
Cancer|June 22, 2021
Surveillance imaging during first remission in follicular lymphoma does not impact overall survivalMax L Goldman, Jimmy J Mao, Christopher S Strouse, et al.
British Journal of Haematology|August 8, 2015
A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphomaJonathon B Cohen, Jeffrey M Switchenko, Jean L Koff, et al.
The Journal of Clinical Investigation|July 21, 2022
Herpes simplex virus lymphadenitis is associated with tumor reduction in a patient with chronic lymphocytic leukemiaAndres Chang, Anton M Sholukh, Andreas Wieland, et al.
Cancer|April 9, 2026
Clinical strategies for lymphoma management: Recommendations from the Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Consensus Conference 2025Alexey V Danilov, Catherine C Coombs, Tycel Phillips, et al.
Hematological Oncology|January 10, 2017
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" studyNarendranath Epperla, Mehdi Hamadani, Amanda F Cashen, et al.
Ejhaem|October 17, 2024
Evaluation of bleeding risk in patients who received pirtobrutinib in the presence or absence of antithrombotic therapyNicole Lamanna, Constantine S Tam, Jennifer A Woyach, et al.
The Lancet. Haematology|February 3, 2019
Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trialLoretta J Nastoupil, Matthew A Lunning, Julie M Vose, et al.
Pageof 13